IntroDia™ is the largest multinational survey of its kind to date which aims to investigate early conversations between physicians and people living with type 2 diabetes and how these conversations may correlate with the individuals’ wellbeing and self-care. Launched in 2013, the survey includes insights from more than 10,000 individuals with type 2 diabetes and more than 6,700 treating physicians across 26 countries. Learn more about the results.
The study is investigating conversations at two distinct milestones: the point of diagnosis of type 2 diabetes, and the moment when additional therapy may be required. The survey insights will be used to develop tools to provide additional support for physicians and people with type 2 diabetes for their early conversations. IntroDia™ was developed by Boehringer Ingelheim and Eli Lilly and Company together with an international multidisciplinary Advisory Board, and in partnership with the International Diabetes Federation (IDF).
-
Introduction to IntroDia™
DOWNLOAD PDF (1.13 MB)
-
Early Conversations T2D
DOWNLOAD PDF (10.76 MB)
-
We interviewed two members of the IntroDia™ Advisory Board.
-
We interviewed healthcare professionals from around the globe at two of the world’s largest diabetes congresses in 2014 to get their thoughts on early conversations in Type 2 Diabetes.
-
Hear more about the importance of conversations held between an individual and their physician.